Vertex Pharmaceuticals

Vertex completes $10 billion Crinetics acquisition, its largest deal ever

Acquirer; Crinetics is now a wholly owned subsidiary

Vertex Pharmaceuticals closed its $10 billion acquisition of Crinetics Pharmaceuticals on September 1, 2026, the largest deal in the company's history. Crinetics shareholders received $85 per share in cash, and the San Diego biotech is now a wholly owned Vertex subsidiary.

Updated Sep 2

The first new class of pain medication in two decades

New Capabilities

Developer and manufacturer of suzetrigine

For more than 20 years, doctors facing patients in severe pain had two choices: prescribe opioids that risked addiction, or use weaker alternatives that often fell short. On January 30, 2025, the Food and Drug Administration (FDA) approved suzetrigine—brand name Journavx—ending that drought as the first entirely new class of pain medication since the late 1990s.

Updated May 27

Generic CF drug crashes price 95%, ending decades of six-figure treatment costs

Rule Changes

Dominant CF treatment manufacturer facing first generic competition

A generic version of Trikafta—the cystic fibrosis drug that extends lives by decades—hit the market at $12,750 per year. That's 95% cheaper than Vertex Pharmaceuticals' brand-name version, which costs over $300,000 annually. The brand-name drug has generated billions while remaining out of reach for patients in developing nations and many Americans with inadequate insurance.

Updated May 20

Vertex Pharmaceuticals

Stories

Vertex completes $10 billion Crinetics acquisition, its largest deal ever

The first new class of pain medication in two decades

Generic CF drug crashes price 95%, ending decades of six-figure treatment costs